These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32660444)

  • 1. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
    BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
    Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
    Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
    Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
    Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer.
    Nomura H; Tsuda H; Susumu N; Fujii T; Banno K; Kataoka F; Tominaga E; Suzuki A; Chiyoda T; Aoki D
    Int J Gynecol Cancer; 2010 Apr; 20(3):341-5. PubMed ID: 20375794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of patients with stage IIIC endometrial cancer.
    Turan T; Ureyen I; Duzguner I; Ozkaya E; Tasci T; Karalok A; Boran N; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2014 Jul; 24(6):1033-41. PubMed ID: 24905617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
    J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of retroperitoneal lymph node metastasis and lymphadenectomy on 3-year survival in ovarian carcinoma].
    Takahashi Y; Akiyama M; Hirose M; Yamamoto Y; Tenzaki T; Ishiguro T; Noda Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Oct; 45(10):1095-100. PubMed ID: 8245587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
    Arikan SK; Kasap B; Yetimalar H; Yildiz A; Sakarya DK; Tatar S
    Asian Pac J Cancer Prev; 2014; 15(15):6087-94. PubMed ID: 25124578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
    Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
    Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To what extent should para-aortic lymphadenectomy be carried out for surgically staged endometrial cancer?
    Dogan NU; Gungor T; Karsli F; Ozgu E; Besli M
    Int J Gynecol Cancer; 2012 May; 22(4):607-10. PubMed ID: 22546819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer--A Single Center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Oct; 35(10):5649-54. PubMed ID: 26408738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
    Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
    Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
    Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
    World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.